China's CDE Launches PIONEER Program, Formally Integrating Organoids and Organ-on-a-Chip into Drug Regulatory Evaluation
Key Insights
China's CDE announced the PIONEER program on July 7, 2026, a five-year pilot to integrate New Approach Methodologies (NAMs) such as organoids and organ-on-a-chips into non-clinical drug evaluation.
The initiative establishes a formal regulatory channel allowing drug developers to submit human-derived model data alongside or in lieu of traditional animal studies for registration applications.
Accepted NAMs methods, once validated through CDE co-developed protocols, can be applied across drug development programs without repeated re-validation, offering material efficiency gains.
On July 7, 2026, China's Center for Drug Evaluation (CDE) (search) under the National Medical Products Administration (NMPA) (search) released a landmark notice launching the "Propel Innovation and Operation of NAMs to Enhance Efficiency in R&D" (PIONEER) program — a structured five-year pilot initiative designed to advance the research, validation, and regulatory application of New Approach Methodologies (NAMs) in drug non-clinical evaluation. The agency has opened a one-month public comment period on three foundational documents: application guidance, an application form, and an implementation framework.
The PIONEER program represents China's first national CDE pilot specifically designed to integrate NAMs — including organoids, organ-on-a-chip systems, in silico computational modeling, in vitro assays, and lower-order organisms — into regulatory non-clinical evaluation. The initiative is framed as a priority action under China's 15th Five-Year Plan for pharmaceutical industry development.
A Structured Regulatory Pathway
PIONEER establishes a formal channel through which drug developers and NAM technology developers can engage the CDE on the use of non-animal, human-biology-relevant methods as part of non-clinical drug evaluation packages. Two eligibility pathways are defined: Scenario 1, for applicants who have already incorporated or plan to incorporate NAMs into non-clinical assessments as supportive data for drug registration; and Scenario 2, for NAM developers seeking methodological cross-validation.
The CDE adopts an approach of "early intervention, timely communication, and full-process tracking" for projects included in the pilot. Accepted projects receive early CDE engagement, ongoing communication, and full-lifecycle tracking, with expert advisory meetings convened to review implementation plans. For cross-validation projects, CDE will co-develop validation protocols with applicants, with the goal of establishing technology-specific standards that — once approved — can be applied across drug development programs without repeated re-validation.
The pilot carries no cap on accepted projects, and accepted methods will be publicly disclosed following a five-business-day notice period. The recruitment period spans five years, with the CDE encouraging joint applications from industry, academia, research institutions, and regulators.
Global Regulatory Context
The PIONEER program arrives amid a broader international shift away from mandatory animal testing. In 2022, the U.S. Congress passed the FDA Modernization Act 2.0, legally allowing pharmaceutical companies to use NAMs data to replace mandatory animal experiment data in Investigational New Drug applications. In April 2025, the FDA announced it would gradually phase out mandatory animal testing requirements for monoclonal antibodies and other drugs. In March 2026, the FDA's Center for Drug Evaluation and Research released a draft guideline clarifying that companies can submit organoid and organ-on-a-chip data directly for non-clinical safety evaluation, requiring only that four principles be met: clear usage scenarios, human biological relevance, reproducible and traceable technology, and suitability for specific regulatory purposes.
The UK's MHRA and Europe's EMA are also advancing their respective acceptance pathways in parallel. The PIONEER program positions China to align more closely with these evolving frameworks, reducing a longstanding source of regulatory uncertainty for multinational developers with China-facing pipelines.
Industrial Momentum
The technology underlying NAMs has reached an inflection point. Organoids — the smallest functional units formed by the self-assembly of stem cells under 3D culture conditions — have been successfully constructed for the liver, kidney, heart, brain, lung, pancreas, and tumor models since Dutch scientists first established intestinal organoids in 2009. Recent breakthroughs include the maturation of vascularized organoids and immune co-culture systems, as well as multi-organ-on-a-chip interconnection systems that simulate metabolic crosstalk between organs.
Multinational pharmaceutical companies are accelerating their adoption. Pfizer, Roche, Merck, Sanofi, and AstraZeneca have all established partnerships with organoid and organ-on-a-chip companies. Sanofi's complement C1s (search)-targeted antibody became the first drug to be approved for a new indication clinical trial based on organoid data. In China, Hengrui Medicine (search)'s novel anti-heart failure drug HRS-1893, screened using a human heart organ-on-a-chip, has obtained clinical approval.
In the first half of 2025, the number of SCI papers published in the organoid field in China reached 811, including 592 original research papers, ranking second globally. In 2026, the National Natural Science Foundation of China set organoids as an independent application code, bringing basic research and funding support into a normalized track. The same year saw more than six financing events disclosed in China's organoid and organ-on-a-chip field, with cumulative financing exceeding 1.1 billion RMB.
Realistic Positioning and Limitations
While organoids are widely regarded as one of the most promising alternatives to animal experiments — their core advantage being "human-derived," directly using human cells to assess drug toxicity and efficacy while avoiding cross-species extrapolation uncertainty — their current limitations are equally clear. They cannot fully simulate systemic effects of multi-organ crosstalk, nor can they easily cover certain chronic long-term toxicity endpoints.
In the short to medium term, their realistic positioning is as follows: in early hit compound screening, lead optimization, preliminary screening of specific organ toxicity, and individualized drug sensitivity testing for rare diseases and tumors, they can prioritize replacing animal experiments; in complete toxicological evaluations, they serve as supplementary evidence forming a "weight of evidence" system with animal data, gradually expanding the scope of substitution.
What to Watch
The public comment window closes in early August 2026. The extent to which CDE incorporates industry and academic feedback will indicate how operationally flexible the program will be in practice. The therapeutic areas and NAM modalities represented in initial PIONEER participants will reveal CDE's near-term priorities — whether focused on specific technologies such as organ-on-a-chip for toxicology, or particular drug classes such as biologics or cell and gene therapies. Additionally, whether CDE formally engages with the FDA's ISTAND program or EU NAM regulatory science initiatives will significantly amplify the strategic value of PIONEER participation for globally active developers.
For pharmaceutical companies, pre-deploying organoid and organ-on-a-chip platforms represents not only a scientific means to reduce clinical failure risk but also compliance preparation for future regulatory expectations. As the CDE noted in its announcement, the initiative establishes an "industry-academia-research-regulator" collaboration mechanism to jointly develop NAM technologies, validation standards, and regulatory science — signaling that regulators are beginning to work alongside enterprises to explore validation standards for a technology still in its early stages.